ImpediMed Limited (IPD) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by and welcome to the Impedimed Limited Q2 FY25 results call. All participants are in a listen-only mode. There will be a presentation followed by a question and answer session. If you wish to ask a question, you will need to press the star key followed by the number 1 on your telephone keypad. We would now like to hand the conference over to Dr. Palmjot Bains, CEO and MD. Please go ahead. Thank you. Good morning and thank you all for joining us to discuss the Q2 FY25 results. I'm pleased to be here with Maguga Grant, our CFO and COO. Today we'll be referencing the 4C quarterly activity report and presentation we lodged this morning with the ASX. The presentation is a summary of the more detailed 4C. After our remarks, we'll be taking questions. I'll begin on page three and quickly go through the agenda for today's call. To page three, consistent with the previous quarter, we will start today with a brief strategy recap. Then we will cover on the key highlights and financial performance for Q2. We will touch on other key metrics in the business. And to finish, we will cover the outlook for the next quarter before commencing the Q&A session. Now, turning to page four. I would think it's worthwhile to start with a reminder of what our immediate strategy is. It's to execute to break even on profitability with a focus on sales, marketing, and clinical execution in BCRL. We've come a long way and made a lot of changes in the 12 months that I've been here. The team has done a lot of work and we're really proud of the achievement that was made. When we assess our achievements against the goals we set in Q3 last year, it's frankly been a bit of a frustrating quarter with delays in US orders coming through despite our pipeline growth. We are focusing no...